Although anti-D prophylaxis by postnatal and antenatal anti-D Ig administration has been highly successful in reducing the incidence of HDFN worldwide [1], it is unnecessary for RhD-negative women who carry an RhD-negative fetus. This evidence concerns the gene RHD and fetal erythroblastosis.